Novelix Pharmaceuticals schedules 32nd AGM for September 30, 2026
- Novelix Pharmaceuticals schedules its 32nd AGM for September 30, 2026
- The meeting will be held via Video Conferencing/OAVM
- Book closure runs from September 24 to September 30, 2026
- Remote e-voting is open from September 27 to September 29, 2026

*this image is generated using AI for illustrative purposes only.
Novelix Pharmaceuticals Limited has scheduled its 32nd Annual General Meeting for September 30, 2026. The meeting will be conducted through Video Conferencing or Other Audio Visual Means (OAVM) in compliance with the Companies Act, 2013.
The company announced the details in a communication to the BSE dated August 31, 2026. The Board of Directors fixed the cut-off date for determining voting eligibility as September 23, 2026.
Meeting and Voting Details
The Register of Members and Share Transfer Books will remain closed from September 24, 2026, to September 30, 2026. This closure ensures the determination of shareholders eligible to attend and vote at the AGM.
Remote e-voting will be available for shareholders who wish to cast their votes before the meeting. The e-voting period begins on September 27, 2026, at 9:00 am and ends on September 29, 2026, at 5:00 pm.
| Event | Date | Time |
|---|---|---|
| Cut-off date for voting eligibility | September 23, 2026 | N/A |
| Book closure start | September 24, 2026 | N/A |
| Remote e-voting start | September 27, 2026 | 9:00 am |
| Remote e-voting end | September 29, 2026 | 5:00 pm |
| AGM Date | September 30, 2026 | 3:00 pm |
The company, formerly known as Trimurthi Limited, is headquartered in Hyderabad, Telangana. Venkateshwarlu Pulluru, Whole-time Director, signed the intimation.
Historical Stock Returns for Trimurthi
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -3.54% | +0.84% | +10.54% | +30.64% | +92.68% | 0.0% |
What key financial results or strategic initiatives is Novelix expected to present to shareholders at the upcoming AGM?
How might the company's recent performance in the pharmaceutical sector influence shareholder voting patterns on executive compensation or dividend proposals?
Are there any anticipated changes to the Board of Directors or management structure that will be discussed during the meeting?


































